🔎 Trials Near Me

Home › Burkitt Lymphoma › California › San Francisco

Burkitt Lymphoma clinical trials in San Francisco, CA

8 studies for Burkitt Lymphoma are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

RecruitingPhase 3
  • Kaiser Permanente-San Francisco, San Francisco
Ages 18 to 39 · All sexes · Updated Oct 2, 2026 · NCT03150693

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingPhase 2
  • UCSF Medical Center-Mission Bay, San Francisco
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RecruitingPhase 3
  • UCSF Medical Center-Mission Bay, San Francisco
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

RecruitingPhase 2
  • UCSF School of Medicine, San Francisco
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

RecruitingPhase 1
  • University of California, San Francisco, San Francisco
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT04545762

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

RecruitingPhase 2
  • UCSF, San Francisco
Ages 1 to 25 · All sexes · Updated May 4, 2025 · NCT03509961

Burkitt Lymphoma trials in other cities

Other studies in San Francisco

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.